BGC
BIB icon

Blue Granite Capital’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

Blue Granite Capital’s Portfolio BIB Stock Details BIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-3,000
Closed -$145K – 112
2017
Q1 		$145K Hold
3,000
– – 0.09% 86
2016
Q4 		$120K Buy
+3,000
New +$128K 0.09% 84

Other funds holding BIB

OPPM
Opus Point Partners Management New York $55.3M AUM 7.48% 1-Year Est. Return
RIA
RPG Investment Advisory Pleasanton, California $829M AUM 36.68% 1-Year Est. Return
CIC
Chase Investment Counsel Charlottesville, Virginia $381M AUM 69.8% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
BA
BKS Advisors Southfield, Michigan $249M AUM 14.37% 1-Year Est. Return
TFA
Toth Financial Advisory Leesburg, Virginia $1.02B AUM 28.36% 1-Year Est. Return
PCA
Private Capital Advisors Darien, Connecticut $872M AUM 26.12% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
BRC
Bell Rock Capital Rehoboth Beach, Delaware $81M AUM 9.85% 1-Year Est. Return

Blue Granite Capital's BIB Position: Q2 2017 in Review

Blue Granite Capital sold out of ProShares Ultra NASDAQ Biotechnology (BIB) in Q2 2017, closing a stake of 3,000 shares — an estimated $145K sold.

Blue Granite Capital first reported a position in BIB in Q4 2016 and held it in 2 quarters. The position peaked at $145K in Q1 2017. 32 funds tracked by Wall St. Rank hold BIB as of Q2 2017.

  • Blue Granite Capital reported no remaining ProShares Ultra NASDAQ Biotechnology position as of Q2 2017 after selling out during the quarter.
  • Blue Granite Capital sold 3,000 ProShares Ultra NASDAQ Biotechnology shares in Q2 2017, an estimated $145K.
  • Blue Granite Capital first reported a position in ProShares Ultra NASDAQ Biotechnology in Q4 2016 and held it in 2 quarters.
  • Blue Granite Capital's ProShares Ultra NASDAQ Biotechnology position peaked at $145K in Q1 2017.
  • 32 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q2 2017.

Based on Blue Granite Capital's 13F filing for Q2 2017, filed 17 Jul 2017.